A study of niraparib in combination with abemaciclib for late line treatment of ovarian cancer: a single center, open label, single arm, phase Ib/II trial (NICHOL TRIAL)

2022-501910-79-01 Phase I and Phase II (Integrated) - First administration to humans Ongoing, recruiting

Start 18 Sep 2024 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - First administration to humans
Status Ongoing, recruiting
Participants planned 73
Countries 1
Sites 1

Ovarian cancer

Key facts

Sponsor
Fondazione IRCCS Istituto Nazionale Dei Tumori
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Female
Therapeutic area
Diseases [C] - Neoplasms [C04], Diseases [C] - Female Urogenital Diseases and Pregnancy Complications [C13]
Trial duration
18 Sep 2024 → ongoing
Decision date (initial)
2024-05-31
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2022-501910-79-01
WHO UTN
U0000-0000-0000
ClinicalTrials.gov
NCT00000000
ISRCTN
ISRCTN00000000

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Ovarian cancer

VersionLevelCodeTermSystem organ class
20.0 PT 10033128 Ovarian cancer 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Fondazione IRCCS Istituto Nazionale Dei Tumori

Sponsor organisation
Fondazione IRCCS Istituto Nazionale Dei Tumori
Address
Via Giacomo Venezian 1
City
Milan
Postcode
20133
Country
Italy

Scientific contact point

Organisation
Fondazione IRCCS Istituto Nazionale Dei Tumori
Contact name
Clinical trial contact point

Public contact point

Organisation
Fondazione IRCCS Istituto Nazionale Dei Tumori
Contact name
public relations office

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Italy Ongoing, recruiting 73 1
Rest of world 0

Investigational sites

Italy

1 site · Ongoing, recruiting
Fondazione IRCCS Istituto Nazionale Dei Tumori
Ginecologia Oncologica, Via Giacomo Venezian 1, 20133, Milan

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Italy 2024-09-18 2024-09-26

Application history

6 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-02-15 Italy Acceptable
2024-05-29
2024-05-31
2 SUBSTANTIAL MODIFICATION SM-1 2024-06-27 Italy Acceptable
2024-07-25
2024-08-01
3 SUBSTANTIAL MODIFICATION SM-2 2025-08-14 Italy Acceptable
2025-09-25
2025-09-26
4 NON SUBSTANTIAL MODIFICATION NSM-1 2025-10-01 Italy Acceptable
2025-09-25
2025-10-01
5 NON SUBSTANTIAL MODIFICATION NSM-2 2025-10-08 Italy Acceptable
2025-09-25
2025-10-08
6 NON SUBSTANTIAL MODIFICATION NSM-3 2025-12-11 Italy Acceptable
2025-09-25
2025-12-11